Readers invited to submit opinions

Adaptive clinical trials require dynamic thinking in many areas, among them cost estimating. As ClearTrial CEO Mike Soenen persuasively explains in our first Op-ed Corner article, applying old cost estimating techniques used in traditional clinical trials will not do for dynamic adaptive trials.

Soenen makes his case well in few words, and I invite all readers who similarly wish to express a biotech IT-related opinion (no announcements or product pitches, please) to submit them to me at [email protected] - George

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.